Expanded Access to Navitoclax
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03592576 |
Expanded Access Status :
No longer available
First Posted : July 19, 2018
Last Update Posted : May 6, 2024
|
Sponsor:
AbbVie
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Condition or disease | Intervention/treatment |
---|---|
Myelofibrosis Acute Lymphocytic Leukemia (ALL) Lymphoblastic Lymphoma | Drug: Navitoclax Drug: Venetoclax |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access to Navitoclax |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Primary myelofibrosis
Drug Information
available for:
Venetoclax
Intervention Details:
- Drug: Navitoclax
Tablet, OralOther Name: ABT-263
- Drug: Venetoclax
Tablet, OralOther Names:
- Venclexta
- ABT-199
- GDC-0199
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years and older (Child, Adult, Older Adult) |
Accepts Healthy Volunteers: | No |
No Contacts or Locations Provided
Responsible Party: | AbbVie |
ClinicalTrials.gov Identifier: | NCT03592576 |
Other Study ID Numbers: |
C19-199 C19-922 ( Other Identifier: AbbVie ) |
First Posted: | July 19, 2018 Key Record Dates |
Last Update Posted: | May 6, 2024 |
Last Verified: | May 2024 |
Keywords provided by AbbVie:
Expanded Access Pre-approval Access Compassionate Use |
Special Access Program Named Patient Basis Special Access Scheme |
Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Leukemia Neoplasms by Histologic Type Neoplasms Hematologic Diseases Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Venetoclax Navitoclax Antineoplastic Agents |